From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
HSD17B13-IN-10 (Compound 464) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. HSD17B13-IN-10 can be used in the research of liver diseases .
HSD17B13-IN-38 (Compound D) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
HSD17B13-IN-13 (Compound 5) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-13 can be used in the research of liver diseases, such as NAFLD .
HSD17B13-IN-44 (Compound 23) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-44 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-67 (Compound 677) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-67 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-73 (Compound 85) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-73 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-70 (Compound 39) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-70 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-6(Compound 475) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. HSD17B13-IN-6can be used in the research of liver diseases .
HSD17B13-IN-76 (Compound 773) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-76 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-74 (Compound 760) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-74 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-46 (Compound 351) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-46 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-45 (Compound 195) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-45 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-47 (Compound 500) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-47 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-72 (Compound 62) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-72 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-77 (Compound 808) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-77 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-38 (Compound 18.02) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
HSD17B13-IN-68 (Compound 16) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-68 can be used for research on liver diseases or metabolic disorders .
HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .
HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with a Ki value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-80 (Compound 151) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-86 (Compound 188) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-86 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-52 (Compound 84) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-52 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-66 (Compound 146) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-66 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-65 (Compound 168) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-65 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-75 (Compound 21) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-75 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-63 (Compound 160) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-63 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-57 (Compound 93) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-57 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-81 (Compound 154) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-81 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-33 (Compound 115) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-33 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-53 (Compound 88) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-53 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-83 (Compound 150) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-83 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-56 (Compound 89) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-51 (Compound 82) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-51 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-48 (Compound 12) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-48 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-82 (Compound 156) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-82 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-71 (Compound 149) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-71 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-55 (Compound 167) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-55 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-61 (Compound 132) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-61 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-54 (Compound 158) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-54 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-79 (Compound 32) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-79 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-64 (Compound 143) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-64 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-99 (Compound 6) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-99 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-60 (Compound 126) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-60 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-59 (Compound 177) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-59 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-15 (Compound 6) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-15 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-32(Compound 67) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-32can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-14 (Compound 4) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-14 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-12 (Compound 3) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. HSD17B13-IN-12 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-11 (Compound 2) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-11 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-94 (Compound 12) is an effective inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for Estradiol (HY-B0141). HSD17B13-IN-94 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD, NASH, or drug-induced liver injury (DILI) .
HSD17B13-IN-93 (Compound 9) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-93 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-91 (Compound 5) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-91 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-80-d2 (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
HSD17B13-IN-80-d2 (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
Inquiry Online
Your information is safe with us. * Required Fields.
